Biomarkers for the mucopolysaccharidoses: Discovery and clinical utility

Molecular Genetics and Metabolism

Volumn 106, Issue 4, 2012, Pages 395-402

  Clarke, Lorne A ^a   Winchester, Bryan ^b   Giugliani, Roberto ^c,d   Tylki Szymańska, Anna ^e   Amartino, Hernan ^f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d INAGEMP   (Brazil)

^e CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^f UNIVERSIDAD AUSTRAL   (Argentina)

Author keywords

Biological markers; Lysosomal storage disease; Mucopolysaccharidoses

Indexed keywords

BIOLOGICAL MARKER; CERAMIDE; DIPEPTIDYL PEPTIDASE IV; GANGLIOSIDE GM2; GANGLIOSIDE GM3; GLYCOSAMINOGLYCAN; GLYCOSPHINGOLIPID; HEPARIN COFACTOR II; OLIGOSACCHARIDE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; BRAIN ATROPHY; BRAIN VENTRICLE DILATATION; CEREBROSPINAL FLUID; COST UTILITY ANALYSIS; ELECTROSPRAY; ENZYME ACTIVITY; HUMAN; IN VIVO STUDY; IONIZATION; LIPOFUSCINOSIS; MUCOPOLYSACCHARIDOSIS; NIEMANN PICK DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TANDEM MASS SPECTROMETRY;

BIOLOGICAL MARKERS; GLYCOSAMINOGLYCANS; HUMANS; MUCOPOLYSACCHARIDOSES;

EID: 84864360492     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.05.003     Document Type: Review

References (77)

1. Kumar R., Amado R.G. Predictive genomic biomarkers. Curr. Top. Microbiol. Immunol. Aug 30 2011, (Electronic publication ahead of print), http://dx.doi.org.10.1007/82_2011_164.
2. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease 2001, 3421-3452. McGraw-Hill, New York. C.R. Scriver (Ed.).
3. Aerts J.M., Kallemeijn W.W., Wegdam W., Joao Ferraz M., van Breemen M.J., Dekker N., Kramer G., Poorthuis B.J., Groener J.E., Cox-Brinkman J., Rombach S.M., Hollak C.E., Linthorst G.E., Witte M.D., Gold H., van der Marel G.A., Overkleeft H.S., Boot R.G. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J. Inherit. Metab. Dis. 2011, 34:605-619.
4. Tomatsu S., Okamura K., Maeda H., Taketani T., Castrillon S.V., Gutierrez M.A., Nishioka T., Fachel A.A., Orii K.O., Grubb J.H., Cooper A., Thornley M., Wraith E., Barrera L.A., Laybauer L.S., Giugliani R., Schwartz I.V., Frenking G.S., Beck M., Kircher S.G., Paschke E., Yamaguchi S., Ullrich K., Haskins M., Isogai K., Suzuki Y., Orii T., Kondo N., Creer M., Okuyama T., Tanaka A., Noguchi A. Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses. J. Inherit. Metab. Dis. 2005, 28:187-202.
5. Tomatsu S., Gutierrez M.A., Ishimaru T., Peña O.M., Montaño A.M., Maeda H., Velez-Castrillon S., Nishioka T., Fachel A.A., Cooper A., Thornley M., Wraith E., Barrera L.A., Laybauer L.S., Giugliani R., Schwartz I.V., Frenking G.S., Beck M., Kircher S.G., Paschke E., Yamaguchi S., Ullrich K., Isogai K., Suzuki Y., Orii T., Noguchi A. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J. Inherit. Metab. Dis. 2005, 28:743-757.
6. Munoz-Rojas M.V., Vieira T., Costa R., Fagondes S., John A., Jardim L.B., Vedolin L.M., Raymundo M., Dickson P.I., Kakkis E., Giugliani R. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am. J. Med. Genet. A 2008, 146A:2538-2544.
7. Bülow H.E., Hobert O. The molecular diversity of glycosaminoglycans shapes animal development. Annu. Rev. Cell Dev. Biol. 2006, 22:375-407.
8. Taylor K.R., Gallo R.L. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J. 2006, 20:9-22.
9. Clarke L.A. The mucopolysaccharidoses: a success of molecular medicine. Expert Rev. Mol. Med. 2008, 10:e1.
10. Bishop J.R., Schuksz M., Esko J.D. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007, 446:1030-1037.
11. Kobialka S., Beuret N., Ben-Tekaya H., Spiess M. Glycosaminoglycan chains affect exocytic and endocytic protein traffic. Traffic 2009, 10:1845-1855.
12. Settembre C., Arteaga-Solis E., Ballabio A., Karsenty G. Self-eating in skeletal development: implications for lysosomal storage disorders. Autophagy 2009, 5:228-229.
13. Lamanna W.C., Lawrence R., Sarrazin S., Esko J.D. Secondary storage of dermatan sulfate in Sanfilippo disease. J. Biol. Chem. 2011, 286:6955-6962.
14. Walkley S.U., Vanier M.T. Secondary lipid accumulation in lysosomal disease. Biochim. Biophys. Acta 2009, 1793:726-736.
15. Heard J.M., Bruyère J., Roy E., Bigou S., Ausseil J., Vitry S. Storage problems in lysosomal diseases. Biochem. Soc. Trans. 2010, 38:1442-1447.
16. de Jong J.G., Hasselman J.J., van Landeghem A.A., Vader H.L., Wevers R.A. The spot test is not a reliable screening procedure for mucopolysaccharidoses. Clin. Chem. 1991, 37:572-575.
17. Kodama C., Kodama T., Yosizawa Z. Methods for analysis of urinary glycosaminoglycans. J. Chromatogr. 1988, 429:293-313.
18. Zaia J. On-line separations combined with MS for analysis of glycosaminoglycans. Mass Spectrom. Rev. 2009, 28:254-272.
19. Auray-Blais C., Bhérer P., Gagnon R., Young S.P., Zhang H.H., An Y., Clarke J.T., Millington D.S. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI. Mol. Genet. Metab. 2011, 102:49-56.
20. Holley R.J., Deligny A., Wei W., Watson H.A., Niñonuevo M.R., Dagälv A., Leary J., Bigger B.W., Kjellén L., Merry C.L. Mucopolysaccharidosis type I, unique structure of accumulated heparan sulfate and increased N-sulfotransferase activity in mice lacking α-l-iduronidase. J. Biol. Chem. 2011, 286:37515-37524.
21. Byers S., Rozaklis T., Brumfield K.L., Ranieri E., Hopwood J. Glycosaminoglycan accumulation and excretion in the mucopolysaccharidosis: characterization and basis of diagnostic test for MPS. Mol. Genet. Metab. 1998, 65:285-290.
22. Clarke L.A., Wraith J.E., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Sidman M., Kakkis E.D., Cox G.F. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009, 123:229-240.
23. Muenzer J., Wraith J.E., Beck M., Giugliani R., Harmatz P., Eng C.M., Vellodi A., Martin R., Ramaswami U., Gucsavas-Calikoglu M., Vijayaraghavan S., Wendt S., Puga A.C., Ulbrich B., Shinawi M., Cleary M., Piper D., Conway A.M., Kimura A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) [published correction appears in Genet Med 9 (2006) 599]. Genet. Med. 2006, 8:465-473.
24. Harmatz P., Giugliani R., Schwartz I., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Yu Z.F., Wittes J., Berger K.I., Newman M.S., Lowe A.M., Kakkis E., Swiedler S.J. MPS VI Phase 3 Study Group, enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr. 2006, 148:533-539.
25. Muenzer J., Beck M., Eng C.M., Giugliani R., Harmatz P., Martin R., Ramaswami U., Vellodi A., Wraith J.E., Cleary M., Gucsavas-Calikoglu M., Puga A.C., Shinawi M., Ulbrich B., Vijayaraghavan S., Wendt S., Conway A.M., Rossi A., Whiteman D.A., Kimura A. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet. Med. 2011, 13:95-101.
26. Muenzer J., Beck M., Giugliani R., Suzuki Y., Tylki-Szymanska A., Valayannopoulos V., Vellodi A., Wraith J.E. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet. Med. 2011, 13:102-109.
27. Schulze-Frenking G., Jones S.A., Roberts J., Beck M., Wraith J.E. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J. Inherit. Metab. Dis. 2011, 34:203-208.
28. Wraith J.E., Beck M., Lane R., van der Ploeg A., Shapiro E., Xue Y., Kakkis E.D., Guffon N. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-l-iduronidase (laronidase). Pediatrics 2007, 120:e37-e46.
29. Wynn R.F., Wraith J.E., Mercer J., O'Meara A., Tylee K., Thornley M., Church H.J., Bigger B.W. Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J. Pediatr. 2009, 154:609-611.
30. Church H., Tylee K., Cooper A., Thornley M., Mercer J., Wraith E., Carr T., O'Meara A., Wynn R.F. Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Bone Marrow Transplant. 2007, 39:207-210.
31. Schwartz I.V., Ribeiro M.B., Mota J.G., Toralles M.B., Correia P., Horovitz D., Santos E.S., Monlleo I.L., Fett-Conte A.C., Sobrinho R.P., Norato D.Y., Paula A.C., Kim C.A., Duarte A.R., Boy R., Valadares E., De Michelena M., Mabe P., Martinhago C.D., Pina-Neto J.M., Kok F., Leistner-Segal S., Burin M.G., Giugliani R. A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr. Suppl. 2007, 96:63-70.
32. Swiedler S.J., Beck M., Bajbouj M., Giugliani R., Schwartz I., Harmatz P., Wraith J.E., Roberts J., Ketteridge D., Hopwood J.J., Guffon N., Sá Miranda M.C., Teles E.L., Berger K.I., Piscia-Nichols C. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am. J. Med. Genet. A 2005, 134A:144-150.
33. Gallegos-Arreola M.P., Machorro-Lazo M.V., Flores-Martinez S.E., Zúñiga-González G.M., Figuera L.E., González-Noriega A., Sánchez-Corona J. Urinary glycosaminoglycan excretion in healthy subjects and in patients with mucopolysaccharidoses. Arch. Med. Res. 2000, 31:505-510.
34. Mahalingam K., Janani S., Priya S., Elango E.M., Sundari R.M. Diagnosis of mucopolysaccharidoses: how to avoid false positives and false negatives. Indian J. Pediatr. 2004, 71:29-32.
35. Glamuzina E., Fettes E., Bainbridge K., Crook V., Finnegan N., Abulhoul L., Vellodi A. Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points. J. Inherit. Metab. Dis. 2011, 34:749-754.
36. Fuller M., Rozaklis T., Ramsay S.L., Hopwood J.J., Meikle P.J. Disease-specific markers for the mucopolysaccharidoses. Pediatr. Res. 2004, 56:733-738.
37. Nielsen T.C., Rozek T., Hopwood J.J., Fuller M. Determination of urinary noligosaccharides by high-performance liquid chromatography/electrospray ionization-tandem mass spectrometry: Application to Hunter syndrome. Anal. Biochem. 2010, 402:113-120.
38. Tomatsu S., Montano A.M., Oguma T., Dung V.C., Oikawa H., Gutiérrez M.L. Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry. Mol. Genet. Metab. 2010, 99:124-131.
39. Tomatsu S., Montaño A.M., Oguma T., Dung V.C., Oikawa H., de Carvalho T.G., Gutiérrez M.L., Yamaguchi S., Suzuki Y., Fukushi M., Sakura N., Barrera L., Kida K., Kubota M., Orii T. Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I. J. Inherit. Metab. Dis. 2010, 33:141-150.
40. Lawrence R., Brown J.R., Al-Mafraji K., Lamanna W.C., Beitel J.R., Boons G.J., Esko J.D., Crawford B.E. Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses. Nat. Chem. Biol. 2012, 8:197-204.
41. Federico A., Capece G., Cecio A., D'Auria N., Di Iorio G., Ronsisvalle L., Di Natale P. Sanfilippo B syndrome (MPS III B): case report with analysis of CSF mucopolysaccharides and conjunctival biopsy. J. Neurol. 1981, 225:77-83.
42. Zhang H., Young S.P., Auray-Blais C., Orchard P.J., Tolar J., Millington D.S. Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry. Clin. Chem. 2011, 57:1005-1012.
43. Randall D.R., Sinclair G.B., Colobong K.E., Hetty E., Clarke L.A. Heparin cofactor II-thrombin complex in MPS I: a biomarker of MPS disease. Mol. Genet. Metab. 2006, 88:235-243.
44. Randall D.R., Colobong K.E., Hemmelgarn H., Sinclair G.B., Hetty E., Thomas A., Bodamer O.A., Volkmar B., Fernhoff P.M., Casey R., Chan A.K., Mitchell G., Stockler S., Melancon S., Rupar T., Clarke L.A. Heparin cofactor II-thrombin complex: a biomarker of MPS disease. Mol. Genet. Metab. 2008, 94:456-461.
45. Langford-Smith K.J., Mercer J., Petty J., Tylee K., Church H., Roberts J., Moss G., Jones S., Wynn R., Wraith J.E., Bigger B.W. Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases. J. Inherit. Metab. Dis. 2011, 34:499-508.
46. Clarke L.A., Hemmelgarn H., Colobong K., Thomas A., Stockler S., Casey R., Chan A., Fernoff P., Mitchell J. Longitudinal observations of serum heparin cofactor II-thrombin complex in treated Mucopolysaccharidosis I and II patients. J. Inherit. Metab. Dis. 2011, 35:355-362.
47. Langford-Smith K., Arasaradnam M., Wraith J.E., Wynn R., Bigger B.W. Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice. Mol. Genet. Metab. 2010, 99:269-274.
48. Beesley C.E., Young E.P., Finnegan N., Jackson M., Mills K., Vellodi A., Cleary M., Winchester B.G. Discovery of a new biomarker for th mucopolysaccharidoses (MPS), dipeptidyl peptidase IV (DPP-IV; CD26), by SELDI-TOF mass spectrometry. Mol. Genet. Metab. 2009, 96:218-224.
49. Constantopoulos G., Dekaban A.S. Neurochemistry of the mucopolysaccharidoses: brain lipids and lysosomal enzymes in patients with four types of mucopolysaccharidosis and in normal controls. J. Neurochem. 1978, 30:965-973.
50. McGlynn R., Dobrenis K., Walkley S.U. Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J. Comp. Neurol. 2004, 480:415-426.
51. Walkley S.U. Pathogenic mechanisms in lysosomal disease: a reappraisal of the role of the lysosome. Acta Paediatr. Suppl. 2007, 96:26-32.
52. Desmaris N., Verot L., Puech J.P., Caillaud C., Vanier M.T., Heard J.M. Prevention of neuropathology in the mouse model of Hurler syndrome. Ann. Neurol. 2004, 56:68-76.
53. Ellinwood N.M., Ausseil J., Desmaris N., Bigou S., Liu S., Jens J.K., Snella E.M., Mohammed E.E., Thomson C.B., Raoul S., Joussemet B., Roux F., Chérel Y., Lajat Y., Piraud M., Benchaouir R., Hermening S., Petry H., Froissart R., Tardieu M., Ciron C., Moullier P., Parkes J., Kline K.L., Maire I., Vanier M.T., Heard J.M., Colle M.A. Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol. Ther. 2011, 19:251-259.
54. Ellinwood N.M., Colle M.A., Weil M.A., Casal M.L., Vite C.H., Wiemelt S., Hasson C.W., O'Malley T.M., He X., Prociuk U., Verot L., Melniczek J.R., Lannon A., Aguirre G.D., Knox V.W., Evans S.M., Vanier M.T., Schuchman E.H., Walkley S.U., Haskins M.E. Bone marrow transplantation for feline mucopolysaccharidosis I. Mol. Genet. Metab. 2007, 91:239-250.
55. Kobayashi T., Beuchat M.H., Chevallier J., Makino A., Mayran N., Escola J.M., Lebrand C., Cosson P., Kobayashi T., Gruenberg J. Separation and characterization of late endosomal membrane domains. J. Biol. Chem. 2002, 277:32157-32164.
56. Meikle P.J., Duplock S., Blacklock D., Whitfield P.D., Macintosh G., Hopwood J.J., Fuller M. Effect of lysosomal storage on bis(monoacylglycero)phosphate. Biochem. J. 2008, 411:71-78.
57. Simonaro C.M., Haskins M.E., Schuchman E.H. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab. Invest. 2001, 81:1319-1328.
58. Simonaro C.M., D'Angelo M., Haskins M.E., Schuchman E.H. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr. Res. 2005, 57:701-707.
59. Simonaro C.M., D'Angelo M., He X., Eliyahu E., Shtraizent N., Haskins M.E., Schuchman E.H. Mechanism of glycosaminoglycan-mediated bone and joint disease: Implications for the mucopolysaccharidoses and other connective tissue diseases. Am. J. Pathol. 2008, 172:112-122.
60. Simonaro C.M., Ge Y., Eliyahu E., He X., Jepsen K.J., Schuchman E.H. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:222-227.
61. Eliyahu E., Wolfson T., Ge Y., Jepsen K.J., Schuchman E.H., Simonaro C.M. Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with Mucopolysaccharidosis type VI. PLoS One 2011, 6:e22447.
62. Di Natale P., Villani G.R., Parini R., Scarpa M., Parenti G., Pontarelli G., Grosso M., Sersale G., Tomanin R., Sibilio M., Barone R., Fiumara A. Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease. Biotechnol. Appl. Biochem. 2008, 49:219-223.
63. Muhlebach M.S., Wooten W., Muenzer J. Respiratory manifestations in mucopolysaccharidoses. Paediatr. Respir. Rev. 2010, 12:133-138.
64. Czartoryska B., Piotrowska E., Wegrzyn A., Wegrzyn G., Malinowska M., Jakóbkiewicz-Banecka J., Kloska A., Tylki-Szymańska A. Abnormalities in the hair morphology of patients with some but not all types of mucopolysaccharidoses. Eur. J. Pediatr. 2008, 167:203-209.
65. Delgadillo V., del Mar O'Callaghan M., Artuch R., Montero R., Pineda M. Genistein supplementation in patients affected by Sanfilippo disease. J. Inherit. Metab. Dis. 2011, 34:1039-1044.
66. Vedolin L., Schwartz I.V., Komlos M., Schuch A., Puga A.C., Pinto L.L., Pires A.P., Giugliani R. Correlation of MR imaging and MR spectroscopy findings with cognitive impairment in mucopolysaccharidosis II. AJNR Am. J. Neuroradiol. 2007, 28:1029-1033.
67. Vedolin L., Schwartz I.V., Komlos M., Schuch A., Azevedo A.C., Vieira T., Maeda F.K., Marques da Silva A.M., Giugliani R. Brain MRI in mucopolysaccharidosis: effect of aging and correlation with biochemical findings. Neurology 2007, 69:917-924.
68. Fan Z., Styner M., Muenzer J., Poe M., Escolar M. Correlation of automated volumetric analysis of brain MR imaging with cognitive impairment in a natural history study of mucopolysaccharidosis II. AJNR Am. J. Neuroradiol. 2010, 31:1319-1323.
69. Davison J.E., Hendriksz C.J., Sun Y., Davies N.P., Gissen P., Peet A.C. Quantitative in vivo brain magnetic resonance spectroscopic monitoring of neurological involvement in mucopolysaccharidosis type II (Hunter Syndrome). J. Inherit. Metab. Dis. Oct 1 2010, (Electronic publication ahead of print), http://dx.doi.org.10.1007/s10545-010-9197-0.
70. Hollak C.E., van Weely S., van Oers M.H., Aerts J.M. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J. Clin. Invest. 1994, 93:1288-1292.
71. Bussink A.P., van Eijk M., Renkema G.H., Aerts J.M., Boot R.G. The biology of the Gaucher cell: the cradle of human chitinases. Int. Rev. Cytol. 2006, 252:71-128.
72. Hollak C., Maas M., Aerts J. Clinically relevant therapeutic endpoints in type 1 Gaucher disease. J. Inherit. Metab. Dis. 2001, 24:97-105.
73. Boot R.G., Renkema G.H., Verhoek M., Strijland A., Bliek J., de Meulemeester T.M., Mannens M.M., Aerts J.M. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J. Biol. Chem. 1998, 273:25680-25685.
74. Schoonhoven, Rudensky B., Elstein D., Zimran A., Hollak C.E., Groener J.E., Aerts J.M. Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin. Chim. Acta 2007, 381:136-139.
75. Grace M.E., Balwani M., Nazarenko I., Prakash-Cheng A., Desnick R.J. Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations - implications for diagnosis and therapeutic monitoring. Hum. Mutat. 2007, 28:866-873.
76. Auray-Blais C., Ntwari A., Clarke J.T., Warnock D.G., Oliveira J.P., Young S.P., Millington D.S., Bichet D.G., Sirrs S., West M.L., Casey R., Hwu W.L., Keutzer J.M., Zhang X.K., Gagnon R. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?. Clin. Chim. Acta 2010, 411:1906-1914.
77. Togawa T., Kodama T., Suzuki T., Sugawara K., Tsukimura T., Ohashi T., Ishige N., Suzuki K., Kitagawa T., Sakuraba H. Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol. Genet. Metab. 2010, 100:257-261.